Anaptysbio (ANAB) Equity Average (2017 - 2025)
Anaptysbio (ANAB) has disclosed Equity Average for 9 consecutive years, with $3.9 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Equity Average fell 94.98% year-over-year to $3.9 million, compared with a TTM value of $3.9 million through Dec 2025, down 94.98%, and an annual FY2025 reading of $54.0 million, down 32.01% over the prior year.
- Equity Average was $3.9 million for Q4 2025 at Anaptysbio, up from -$37.1 million in the prior quarter.
- Across five years, Equity Average topped out at $389.3 million in Q1 2021 and bottomed at -$37.1 million in Q3 2025.
- Average Equity Average over 5 years is $181.0 million, with a median of $152.1 million recorded in 2023.
- The sharpest move saw Equity Average increased 3.73% in 2021, then tumbled 178.68% in 2025.
- Year by year, Equity Average stood at $370.0 million in 2021, then decreased by 27.07% to $269.9 million in 2022, then tumbled by 61.37% to $104.2 million in 2023, then decreased by 25.54% to $77.6 million in 2024, then crashed by 94.98% to $3.9 million in 2025.
- Business Quant data shows Equity Average for ANAB at $3.9 million in Q4 2025, -$37.1 million in Q3 2025, and -$5.4 million in Q2 2025.